Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas

[1] Clark MA(2005)Soft-tissue sarcomas in adults N Engl J Med 353 701-711

[2] Fisher C(2020)Heterogeneity of soft tissue sarcomas and its implications in targeted therapy Front Oncol 10 1-3

[3] Judson I(2020)Soft-tissue sarcoma in adults: An update on the current state of histotype-specific management in an era of personalized medicine CA Cancer J Clin 70 200-229

[4] Thomas JM(2005)Soft-tissue sarcomas of the chest wall: prognostic factors Chest 127 902-908

[5] Du XH(2018)Primary pulmonary sarcoma-long-term treatment outcomes and prognostic factors Kardiochirurgia i Torakochirurgia Pol 15 162-169

[6] Wei H(2014)Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Lancet Oncol 15 415-423

[7] Zhang P(2016)Radiation therapy for soft tissue sarcoma: indications and controversies for neoadjuvant therapy, adjuvant therapy, intraoperative radiation therapy, and brachytherapy Surg Oncol Clin N Am 25 841-860

[8] Yao WT(2017)VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma Med (united States) 96 1-6

[9] Cai QQ(2000)The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma Cancer 89 177-180

[10] Gamboa AC(2008)A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma Cancer 113 573-581

[1] Clark MA(2005)Soft-tissue sarcomas in adults N Engl J Med 353 701-711

[2] Fisher C(2020)Heterogeneity of soft tissue sarcomas and its implications in targeted therapy Front Oncol 10 1-3

[3] Judson I(2020)Soft-tissue sarcoma in adults: An update on the current state of histotype-specific management in an era of personalized medicine CA Cancer J Clin 70 200-229

[4] Thomas JM(2005)Soft-tissue sarcomas of the chest wall: prognostic factors Chest 127 902-908

[5] Du XH(2018)Primary pulmonary sarcoma-long-term treatment outcomes and prognostic factors Kardiochirurgia i Torakochirurgia Pol 15 162-169

[6] Wei H(2014)Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Lancet Oncol 15 415-423

[7] Zhang P(2016)Radiation therapy for soft tissue sarcoma: indications and controversies for neoadjuvant therapy, adjuvant therapy, intraoperative radiation therapy, and brachytherapy Surg Oncol Clin N Am 25 841-860

[8] Yao WT(2017)VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma Med (united States) 96 1-6

[9] Cai QQ(2000)The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma Cancer 89 177-180

[10] Gamboa AC(2008)A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma Cancer 113 573-581